Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
Four major guinea-pig blood vessels were isolated and studied in vitro for their contractile responses to anaphylatoxins C3a and C5a. Both peptides were assayed in the 10(-9) to 10(-7) M range and their effects were parallel, although C3a was less potent and more tachyphylactic than C5a. The most responsive blood vessel, relative to a histamine maximal response, was the portal vein, followed by the pulmonary artery and the thoracic aorta. The abdominal vena cava did not respond to either C3a or C5a. Participation of secondary mediators in the vasoconstrictor effect of C3a and C5a was assessed by exposing portal veins and pulmonary arteries to specific inhibitors. The four drugs were: indomethacin, a cyclooxygenase inhibitor; pyrilamine, an antagonist of H1 receptors for histamine; FPL55712, an antagonist of the leukotriene component of slow-reacting substance of anaphylaxis; and phentolamine, an alpha adrenergic blocker. This pharmacological analysis suggests that prostaglandin-like substances mediate most of the anaphylatoxin vasoconstrictor effects, with a biologically significant participation of leukotrienes in the case of C3a and histamine in the case of C5a. High variability between individual tissue responses to the anaphylatoxins was investigated in terms of previous exposure to activated complement. Cobra venom factor (200 micrograms) was injected i.v. in five guinea pigs 2 hr before sacrifice. This treatment reduced the serum concentration of C3 and C5 to 9 and 32%, respectively, as compared with saline-treated animals. The portal vein excised from the cobra venom factor-treated animals exhibited reduced sensitivities to C3a, but showed normal response to C5a. The selective desensitization to C3a after complement activation in vivo is presumably related to the highly tachyphylactic effect of C3a on blood vessels.
D000706:Anaphylatoxins; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology; D003176:Complement C3 / Q000494:pharmacology*; D015926:Complement C3a; D003182:Complement C5 / Q000494:pharmacology*; D015936:Complement C5a; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D006461:Hemolysis; D006632:Histamine / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010455:Peptides; D011738:Pyrilamine / Q000494:pharmacology; D013618:Tachyphylaxis
D000706:Anaphylatoxins; D002867:Chromones; D003176:Complement C3; D003182:Complement C5; D010455:Peptides; D015926:Complement C3a; D015936:Complement C5a; D006632:Histamine; C006312:FPL 55712; D011738:Pyrilamine; D001241:Aspirin; D009638:Norepinephrine; D007213:Indomethacin